OTCMKTS:MMEDF Mind Medicine (MindMed) (MMEDF) Stock Price, News & Analysis $34.18 -0.91 (-2.59%) As of 10/8/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Mind Medicine (MindMed) Stock (OTCMKTS:MMEDF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MMEDF alerts:Sign Up Key Stats Today's Range$32.84▼$34.8850-Day Range$34.18▼$46.1852-Week Range$0.29▼$5.07Volume2.10 million shsAverage Volume3.38 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing therapies for brain health and psychiatric disorders. The company researches medicines derived from or inspired by psychedelic and empathogenic compounds, with the goal of addressing conditions that may not respond adequately to existing treatments. MindMed’s lead program, MM120, is an orally administered formulation of lysergide, commonly known as LSD, being evaluated for anxiety and other psychiatric disorders. The company has also advanced MM402, an investigational therapy based on the R-enantiomer of MDMA, for potential use in neuropsychiatric conditions including autism spectrum disorder. Its programs are subject to clinical testing and regulatory review. Founded in 2019, MindMed conducts research and clinical development activities in the United States and works with academic, medical and research partners. Robert Barrow serves as the company’s chief executive officer and has been associated with its efforts to advance psychedelic-inspired medicines through clinical development.AI Generated. May Contain Errors. Read More Receive MMEDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MMEDF Stock News HeadlinesMind Medicine (MNMD) price target increased by 11.49% to 29.15January 14, 2026 | msn.comJones Trading initiates coverage of Mind Medicine (MNMD) with buy recommendationDecember 24, 2025 | msn.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer. | Weiss Ratings (Ad)Mind Medicine initiated with a Buy at JonesResearchDecember 23, 2025 | msn.comCanaccord Genuity Maintains Mind Medicine (MNMD) Buy RecommendationNovember 8, 2025 | msn.comMind Medicine initiated with a Buy at NeedhamOctober 13, 2025 | msn.comMind Medicine participates in a conference call with Cantor FitzgeraldSeptember 22, 2025 | msn.comPsychedelic: Exclusive talk with biopharma company MindMedSeptember 18, 2025 | msn.comSee More Headlines MMEDF Stock Analysis - Frequently Asked Questions How have MMEDF shares performed this year? Mind Medicine (MindMed)'s stock was trading at $13.06 on January 1st, 2026. Since then, MMEDF shares have increased by 161.7% and is now trading at $34.18. How do I buy shares of Mind Medicine (MindMed)? Shares of MMEDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:MMEDF CIKN/A Webwww.mindmed.co Phone(212) 220-6633FaxN/AEmployees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:MMEDF) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.